Osteonecrosis.
Conditions
Interventions
Intervention 1: Intervention group: Includes patients whose multi-target therapies such as atorvastatin 40 mg daily, vitamin E (400 mg) daily, and aspirin 80 mg daily are added to their bisphosphonate
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with autoimmune connective tissue diseases and vasculitis Requires treatment with high doses of corticosteroids
Exclusion criteria
Exclusion criteria: Co-occurrence of antiphospholipid syndrome Taking drugs that increase the risk of coagulation, such as oral contraceptives Occurrence of events leading to increased coagulation such as long-term hospitalization, trauma leading to surgery Taking anticoagulants Occurrence of adverse drug reactions in the course of patient examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evidence of Osteonecrosis following high-dose Corticosteroids. Timepoint: In the first three months after starting Corticosteroid and also one year after starting it. Method of measurement: Three-phasic bone scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of side effects of drugs. Timepoint: Monthly. Method of measurement: History and Laboratory findings. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Loghman
Tehran University of Medical Sciences
Outcome results
None listed